# US 2025/0205259 A1 · Class of 7-((five-membered heterocyclic)methyl)-8-carboxylic acid-benzo cyclic borate derivatives and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205259 A1
- Document ID: US20250205259A1
- Status: Published application
- Kind: A1
- Application number: 18/991,883
- Filed: 2024-12-23
- Published: 2025-06-26
- Earliest claimed: 2022-07-05
- Assignees: Fuan Pharmaceutical Group Chongqing Sunhorizon Pharm-Tech Co., Ltd
- Applicants: Fuan Pharmaceutical Group Chongqing Sunhorizon Pharm-Tech Co., Ltd
- Inventors: Guobo LI
- Web page: https://patentgrep.com/patent/US20250205259A1

## CPC

- A61K 31/69: Boron compounds
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61P 31/04: Antibacterial agents
- C07F 5/02: Boron compounds
- C07F 5/025: {Boronic and borinic acid compounds}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Provided are a class of 7-((five-membered heterocyclic)methyl)-8-carboxylic acid-benzo cyclic borate derivatives represented by formula (I) and uses thereof. The derivative has good broad-spectrum inhibitory activity on clinically common metallo-β-lactamase (MBL) and serine-β-lactamase (SBL), can be used as an inhibitor of MBL and/or SBL, and is used for preparing antibacterial drugs, especially drugs against drug-resistant bacteria. In addition, the derivative is combined with β-lactam antibiotics, has good antibacterial activity on various β-lactam antibiotic-resistant bacteria, has a very great potential in preparing MBL and SBL dual broad-spectrum inhibitors and drugs for overcoming β-lactam antibiotic-resistant bacteria, provides a new choice for the use of the antibacterial drugs, and has a good application prospect.

## Claims

### Claim 1

A compound represented by formula I, or a salt, a conformational isomer or an optical isomer thereof,
wherein,
n is an integer of 0 to 5,
R1 is selected from the group consisting of hydrogen, substituted or unsubstituted C1-C8alkyl, C1-C8alkoxy, halogen, hydroxyl, amino, nitro, carboxyl, cyano and SR9,
A ring is a five-membered unsaturated heterocyclic ring, wherein X, Y, Z, W and U are independently selected from the group consisting of C, CR8 and N,
R2, R3, R4 and R5 are substituents on ring A, and R2, R3, R4 and R5 are independently selected from the group consisting of absence, hydrogen, halogen, hydroxyl, amino, nitro, carboxyl, cyano, amido, quaternary ammonium salt, substituted or unsubstituted C1-C8alkyl, substituted or unsubstituted C2-C8 alkynyl, C1-C8alkoxy, substituted or unsubstituted 3- to 8-membered cycloalkyl, substituted or unsubstituted 4- to 8-membered heterocycloalkyl, substituted or unsubstituted 5- to 8-membered aryl, substituted or unsubstituted 5- to 8-membered heteroaryl, and —COR10,
alternatively, any two adjacent positions in R2, R3, R4, and R5 are connected to form substituted or unsubstituted 3- to 8-membered cycloalkyl, substituted or unsubstituted 4- to 8-membered heterocycloalkyl, substituted or unsubstituted 5- to 8-membered aryl, or substituted or unsubstituted 5- to 8-membered heteroaryl,
R6 and R7 are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C8alkyl, C1-C8alkoxy, halogen, hydroxyl, amino, nitro, carboxyl, and cyano,
R8 is selected from the group consisting of hydrogen, halogen, hydroxyl, amino, nitro, carboxyl, cyano, amido, quaternary ammonium salt, substituted or unsubstituted C1-C8 alkyl, C1-C8 alkoxy, substituted or unsubstituted 3- to 8-membered cycloalkyl, substituted or unsubstituted 4- to 8-membered heterocycloalkyl, substituted or unsubstituted 5- to 8-membered aryl, and substituted or unsubstituted 5- to 8-membered heteroaryl,
R9 is a five-membered unsaturated heterocyclic group,
R10 is selected from the group consisting of amino, 4- to 8-membered heterocycloalkyl and amino-substituted 4- to 8-membered heterocycloalkyl,
a substituent on the alkyl is selected from the group consisting of halogen, hydroxyl, amino, nitro, carboxyl, cyano, guanidino, quaternary ammonium salt, sulfonamido, and substituted or unsubstituted 4- to 8-membered heterocycloalkyl;
a substituent on the alkynyl, the cycloalkyl, the heterocycloalkyl, the aryl, and the heteroaryl is selected from the group consisting of C1-C8 alkyl, C1-C8 aliphatic amine group, C1-C8 alkoxy, halogen, hydroxyl, amino, nitro, carboxyl, cyano, guanidino, and sulfonamido,
a heteroatom on the heterocycloalkyl and the heteroaryl is selected from the group consisting of N, O and S, and a number of the heteroatom is selected from the group consisting of 1, 2, 3, 4 and 5, and
one or more hydrogen atoms on the amino can be further substituted with a substituent selected from the group consisting of C1-C8 alkyl, C1-C8 aliphatic amine group and sulfonamido.

### Claim 2 (depends on 1)

The compound, or the salt, the conformational isomer or the optical isomer thereof according to claim 1, wherein
n is selected from the group consisting of 0, 1, 2, 3, 4 and 5,
R1 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkoxy, halogen, hydroxyl, amino, nitro, carboxyl, cyano and SR9,
A ring is a five-membered unsaturated heterocyclic ring, wherein X is selected from the group consisting of C, CR8 and N, Y is N, Z is selected from the group consisting of C, CR8 and N, W is selected from the group consisting of C and N, and U is selected from the group consisting of C and N,
R2, R3, R4 and R5 are substituents on ring A, and R2, R3, R4 and R5 are independently selected from the group consisting of absence, hydrogen, halogen, hydroxyl, amino, nitro, carboxyl, cyano, amido, quaternary ammonium salt, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C2-C4 alkynyl, C1-C4 alkoxy, substituted or unsubstituted 3- to 6-membered cycloalkyl, substituted or unsubstituted 4- to 6-membered heterocycloalkyl, substituted or unsubstituted 5- to 6-membered aryl, substituted or unsubstituted 5- to 6-membered heteroaryl, and —COR10,
alternatively, any two adjacent positions in R2, R3, R4, and R5 are connected to form substituted or unsubstituted 3- to 6-membered cycloalkyl, substituted or unsubstituted 4- to 6-membered heterocycloalkyl, substituted or unsubstituted 5- to 6-membered aryl, or substituted or unsubstituted 5- to 6-membered heteroaryl,
R6 and R7 are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C4 alkyl, C1-C4 alkoxy, halogen, hydroxyl, amino, nitro, carboxyl, and cyano,
R8 is selected from the group consisting of hydrogen, halogen, hydroxyl, amino, nitro, carboxyl, cyano, amido, quaternary ammonium salt, substituted or unsubstituted C1-C4 alkyl, C1-C4 alkoxy, substituted or unsubstituted 3- to 6-membered cycloalkyl, substituted or unsubstituted 4- to 6-membered heterocycloalkyl, substituted or unsubstituted 5- to 6-membered aryl, and substituted or unsubstituted 5- to 6-membered heteroaryl,
R9 is a five-membered unsaturated heterocyclic group, wherein a heteroatom on the heterocyclic group is selected from the group consisting of N, O, S, and a combination thereof,
R10 is selected from the group consisting of amino, 4- to 5-membered heterocycloalkyl and amino-substituted 4- to 5-membered heterocycloalkyl,
a substituent on the alkyl is selected from the group consisting of halogen, hydroxyl, amino, nitro, carboxyl, cyano, guanidino, quaternary ammonium salt, sulfonamido, and substituted or unsubstituted 4- to 6-membered heterocycloalkyl;
a substituent on the alkynyl, the cycloalkyl, the heterocycloalkyl, the aryl, and the heteroaryl is selected from the group consisting of C1-C4 alkyl, C1-C4 aliphatic amine group, C1-C4 alkoxy, halogen, hydroxyl, amino, nitro, carboxyl, cyano, guanidino, and sulfonamido,
a heteroatom on the heterocycloalkyl and the heteroaryl is selected from the group consisting of N, O and S, and a number of the heteroatom is 1 or 2, and
one or more hydrogen atoms of the amino can be further substituted with a substituent selected from the group consisting of C1-C4 alkyl, C1-C4 aliphatic amine group and sulfonamido.

### Claim 3 (depends on 1)

The compound, or the salt, the conformational isomer or the optical isomer thereof according to claim 1, wherein A ring is selected from the group consisting of:

### Claim 4 (depends on 1)

The compound, or the salt, the conformational isomer or the optical isomer thereof according to claim 1, wherein the compound has a structure represented by formula II:
wherein n, A ring, X, Y, Z, W, U, R1, R2, R3, R4 and R5 are each selected as defined in claim 1.

### Claim 5 (depends on 1, 4)

The compound, or the salt, the conformational isomer or the optical isomer thereof according to claim 4, wherein the compound has a structure represented by formula III:
wherein A ring, X, Y, Z, W, U, R1, R2, R3, R4 and R5 are each selected as defined in claim 1;
alternatively, the compound has a structure represented by formula IV:
wherein A ring, X, Y, Z, W, U, R2, R3, R4 and R5 are each selected as defined in claim 1.

### Claim 6 (depends on 1, 5)

The compound, or the salt, the conformational isomer or the optical isomer thereof according to claim 5, wherein the compound has a structure represented by formula V:
wherein A ring, X, Y, Z, W, U, R2, R3, R4 and R5 are each selected as defined in claim 1.

### Claim 7 (depends on 1)

The compound, or the salt, the conformational isomer or the optical isomer thereof according to claim 1, wherein the compound has a structure represented by formula VI-1:
wherein, R3 and R4 are each selected as defined in claim 1;
alternatively, the compound has a structure represented by formula VI-2:
wherein, R4 and R5 are each selected as defined in claim 1;
alternatively, the compound has a structure represented by formula VI-3:
wherein, R2 and R4 are each selected as defined in claim 1;
alternatively, the compound has a structure represented by formula VI-4:
wherein, R2, R3 and R4 are each selected as defined in claim 1;
alternatively, the compound has a structure represented by formula VI-5:
wherein, R2, R4 and R5 are each selected as defined in claim 1;
alternatively, the compound has a structure represented by formula VI-6:
wherein, R2, R3, R4 and R5 are each selected as defined in claim 1;
alternatively, the compound has a structure represented by formula VI-7:
alternatively, the compound has a structure represented by formula VI-8:
wherein, R2, R3, R4 and R5 are each selected as defined in claim 1;
R81 and R82 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, nitro, carboxyl, cyano, amido, quaternary ammonium salt, substituted or unsubstituted C1-C4 alkyl, C1-C4 alkoxy, substituted or unsubstituted 3- to 6-membered cycloalkyl, substituted or unsubstituted 4- to 6-membered heterocycloalkyl, substituted or unsubstituted 5- to 6-membered aryl, and substituted or unsubstituted 5- to 6-membered heteroaryl;
a substituent on the alkyl is selected from the group consisting of halogen, hydroxyl, amino, nitro, carboxyl, cyano, guanidino, quaternary ammonium salt, and substituted or unsubstituted 4- to 6-membered heterocycloalkyl;
a substituent on the cycloalkyl, the heterocycloalkyl, the aryl, and the heteroaryl is selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halogen, hydroxyl, amino, nitro, carboxyl, and cyano; and
a heteroatom on the heterocycloalkyl and the heteroaryl is selected from the group consisting of N, O and S, and a number of the heteroatom is 1 or 2.

### Claim 8 (depends on 1)

The compound, or the salt, the conformational isomer or the optical isomer thereof according to claim 1, wherein the compound is selected from the group consisting of:

### Claim 9 (depends on 1)

A method of exposing a subject in need thereof to a metallo-β-lactamase and/or serine-β-lactamase inhibitor treatment, comprising administering the compound, or the salt, the conformational isomer or the optical isomer thereof according to claim 1 to the subject.

### Claim 10 (depends on 1)

A method of exposing a subject in need thereof to an antibacterial medicament treatment, comprising administering the compound, or the salt, the conformational isomer or the optical isomer thereof according to claim 1 to the subject,
preferably, the antibacterial medicament is a medicament against drug-resistant bacteria, and
more preferably, the medicament against drug-resistant bacteria is a medicament against β-lactam antibiotic-resistant bacteria.

### Claim 11 (depends on 1)

A medicament, which is a formulation obtained by using the compound, or the salt, the conformational isomer or the optical isomer thereof according to claim 1 as an active ingredient, and a pharmaceutically acceptable excipient or an auxiliary ingredient.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising the compound, or the salt, the conformational isomer or the optical isomer thereof according to claim 1, and an antibiotic,
preferably, the antibiotic is a β-lactam antibiotic, and
more preferably, the antibiotic is selected from the group consisting of meropenem, imipenem, cefepime, and a combination thereof.

### Claim 13 (depends on 1)

A method of exposing a subject in need thereof to an antibacterial medicament treatment, comprising administering the compound, or the salt, the conformational isomer or the optical isomer thereof according to claim 1 in combination with an antibiotic to the subject,
preferably, the antibacterial medicament is a medicament against drug-resistant bacteria, and/or the antibiotic is a β-lactam antibiotic, and
more preferably, the medicament against drug-resistant bacteria is a medicament against β-lactam antibiotic-resistant bacteria, and/or the antibiotic is selected from the group consisting of meropenem, imipenem, cefepime, and a combination thereof.
